Solvay Pharmaceuticals to Co-Promote Abbott’s SIMCOR in the United States
Solvay Pharmaceuticals has entered into an agreement granting Solvay select co-promotion rights in the United States for Abbott’s investigational fixed-dose combination lipid therapy, SIMCOR® (Niaspan®/simvastatin), currently awaiting U.S. Food and Drug Administration (FDA) approval.
Under the terms of the agreement, Solvay will provide sales support in the United States, contribute to development and promotional expenses and be compensated based on product sales. Specific financial terms were not disclosed.
SIMCOR combines two well-established and leading medications, Niaspan and simvastatin, to target multiple lipid parameters - LDL “bad” cholesterol, HDL, “good” cholesterol and triglycerides – in a single pill. Abbott submitted its New Drug Application to the FDA for SIMCOR in April 2007.
SIMCOR builds upon an ongoing agreement between Abbott and Solvay Pharmaceuticals involving the commercialization and development of fenofibrate, and continues both companies’ commitment toward the treatment of lipid disorders.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.